Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
DTP-HepB vaccine
Подписчиков: 0, рейтинг: 0
Combination of | |
---|---|
DTP vaccine | Vaccine |
Hepatitis B vaccine | Vaccine |
Clinical data | |
Trade names | Tritanrix-HepB |
AHFS/Drugs.com | UK Drug Information |
Routes of administration |
Intramuscular injection |
ATC code | |
Identifiers | |
CAS Number |
DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B.
A branded formulation, Tritanrix-HepB manufactured by GlaxoSmithKline, was granted marketing approval in the EU in 1996. Marketing approval lapsed in 2014.
A review conducted in 2012 concluded that there was insufficient evidence to determine differences in safety and efficacy between DTP-HepB vaccine and Hib vaccine administered separately and pentavalent DTP-HepB-Hib vaccine.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
|
||||||||||
Inventors/ researchers |
|||||||||||
Controversy | |||||||||||
Related | |||||||||||
|